Agile Therapeutics, Inc. (AGRX)

NASDAQ: AGRX · IEX Real-Time Price · USD
0.00 (0.00%)
May 26, 2022 4:00 PM EDT - Market closed

Company Description

Agile Therapeutics, Inc., a women's healthcare company, researches, develops, and commercializes prescription contraceptive products for women in the United States.

Its lead product is Twirla, also known as AG200-15, a once-weekly prescription combination hormonal contraceptive patch. The company is also developing a pipeline of Twirla line extensions and other products, including AG200-15 Extended Regimen (ER), a regimen that allows a woman to have four episodes of withdrawal bleeding per year; AG200-15 smaller patch (SmP), which is a regimen designed to provide shorter and lighter withdrawal bleeds, and enhance contraceptive efficacy; AG200-15 ER SmP, a regimen to allow a woman to extend the length of her contraceptive cycle, as well as have shorter and lighter withdrawal bleeding episodes per year; and P-Patch, a progestin-only contraceptive patch intended for use by women who are unable or unwilling to take estrogen.

Agile Therapeutics, Inc. was incorporated in 1997 and is headquartered in Princeton, New Jersey.

Agile Therapeutics, Inc.
Agile Therapeutics Logo
CountryUnited States
IPO DateMay 23, 2014
SectorHealth Care
CEOAlfred Altomari

Contact Details

101 Poor Farm Rd
Princeton, New Jersey 08540-1941
United States
Phone609 683 1880

Stock Details

Ticker SymbolAGRX
Fiscal YearJanuary - December
Reporting CurrencyUS Dollars
CIK Code0001261249

Key Executives

Alfred F. AltomariChairman and Chief Executive Officer
Geoffrey P. GilmoreSenior Vice President, General Counsel and Corporate Secretary
Dr. Paul Korner M.B.A., M.D.Senior Vice President and Chief Medical Officer
Dennis P. ReillySenior Vice President and Chief Financial Officer
Jason ButchVice President and Chief Accounting Officer
Matthew RileyHead of Investor Relations and Corporate Communications
Amy WelshVice President of Marketing
Robert G. Conway M.E.Senior Vice President and Chief Supply Chain Officer
Dr. Elizabeth Ijeoma Onyemelukwe Garner M.D., M.P.H.Consultant
Joseph D'UrsoController

Latest SEC Filings

May 24, 20228-KCurrent report
May 23, 20228-KCurrent report
May 13, 2022S-1General form for registration of securities under the Securities Act of 1933
May 12, 202210-QQuarterly report [Sections 13 or 15(d)]
May 12, 20228-KCurrent report
Apr 29, 2022DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) material
Apr 29, 2022DEF 14AOther definitive proxy statements
Apr 27, 20228-KCurrent report
Apr 27, 2022424B5Prospectus [Rule 424(b)(5)]
Apr 26, 20228-KCurrent report
View All SEC Filings